HOOKIPA Pharma Inc
NASDAQ:HOOK
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.7900
  • TODAY'S CHANGE (%)
    0.0237 (3.0928%)
  • Bid / Lots
    0.7703/ 4
  • Ask / Lots
    0.7900/ 29
  • Open / Previous Close
    0.7660 / 0.7663
  • Day Range
    0.7550
    0.7926
  • 52 Week Range
    0.4100
    2.0000
  • Volume
    95,404

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
HOOK
HOOKIPA Pharma Inc
75.8M
0.0x
---
As of 2024-05-14

Company Information

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Contact Information

Headquarters
350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118
Phone
---
Fax
302-655-5049

Executives

No data available

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$75.8M
Revenue (TTM)
$53.6M
Shares Outstanding
99.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.75
EPS
$-0.59
Book Value
$0.91
P/E Ratio
0.0x
Price/Sales (TTM)
1.4
Price/Cash Flow (TTM)
---
Operating Margin
-119.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.